These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 14963790)

  • 1. [Hemosiderosis in Chronic Hepatitis C: Should Venesection Precede Treatment with Interferon-alpha and Ribavirin?].
    Bauditz J; Roske AE; Schmidt HH
    Z Gastroenterol; 2004 Feb; 42(2):167-70. PubMed ID: 14963790
    [No Abstract]   [Full Text] [Related]  

  • 2. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload.
    Coelho-Borges S; Cheinquer H; Cheinquer N; Krug L; Ashton-Prolla P
    Am J Gastroenterol; 2002 Jun; 97(6):1570-2. PubMed ID: 12094895
    [No Abstract]   [Full Text] [Related]  

  • 3. Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C.
    Azim J; McCurdy H; Moseley RH
    World J Gastroenterol; 2008 Oct; 14(38):5913-5. PubMed ID: 18855993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C].
    Zeuzem S
    Dtsch Med Wochenschr; 1999 May; 124(20):636-42. PubMed ID: 10370387
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
    Adinolfi LE; Durante Mangoni E; Andreana A
    Am J Gastroenterol; 2001 Feb; 96(2):607-8. PubMed ID: 11232725
    [No Abstract]   [Full Text] [Related]  

  • 6. Sequential antiviral and iron chelation treatment in a teenage boy with congenital anemia, chronic hepatitis C, and secondary hemosiderosis.
    Yap J; O'Connor C; Kirby M; Guindi M; Roberts EA
    J Pediatr Gastroenterol Nutr; 2009 Mar; 48(3):382-5. PubMed ID: 19274798
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of chronic hepatitis C].
    Bell H; Dalgard O; Bjøro K; Hellum KB; Myrvang B
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):926-8. PubMed ID: 12082838
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.
    Bhatti A; McGarrity TJ; Gabbay R
    Am J Gastroenterol; 2001 Feb; 96(2):604-5. PubMed ID: 11232722
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-transferrin-bound iron in untreated and ribavirin-treated chronic hepatitis C patients.
    Van Vlierberghe H; Verdievel H; Colle I; Delanghe J; Praet M; Bernard D; Leroux-Roels G; De Vos M
    Aliment Pharmacol Ther; 2002 Aug; 16(8):1555-62. PubMed ID: 12182756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 11. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
    Kasahara A
    J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
    [No Abstract]   [Full Text] [Related]  

  • 12. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of iron and HFE mutations on response to therapy in chronic hepatitis C: an ironic interaction?
    Alexander J; Kowdley KV
    Gastroenterology; 2006 Nov; 131(5):1635-8. PubMed ID: 17067603
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 15. Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection.
    Papastathopoulos K; Bouzas E; Naoum G; Vergados I; Tsiodras S
    J Infect; 2006 Feb; 52(2):e59-61. PubMed ID: 15951019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapeutic possibilities in chronic hepatitis C].
    Criblez DH
    Praxis (Bern 1994); 2000 Mar; 89(11):450-3. PubMed ID: 10758732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection.
    Shen Y; Pielop J; Hsu S
    Arch Dermatol; 2005 Jan; 141(1):102-3. PubMed ID: 15655158
    [No Abstract]   [Full Text] [Related]  

  • 18. [APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():74-5. PubMed ID: 15373058
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
    Enjoji M; Dainichi T; Gondo H; Urabe K
    Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin.
    Weegink CJ; Chamuleau RA; Reesink HW; Molenaar DS
    J Gastroenterol; 2001 Oct; 36(10):723-4. PubMed ID: 11686485
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.